Raymond James Starts Gemphire Therapeutics (GEMP) Coverage with $22.0000 Target; Scopia Capital Management LP Has Upped By $61.65 Million Its Gw Pharmaceuticals Plc (GWPH) Position

May 17, 2018 - By Migdalia James

In a analysts note sent to clients and investors on 16 May, Raymond James analyst just has started coverage of Gemphire Therapeutics (GEMP) with “Buy” rating. The target price is exactly $22.0000.

Scopia Capital Management Lp increased Gw Pharmaceuticals Plc (GWPH) stake by 15.63% reported in 2017Q4 SEC filing. Scopia Capital Management Lp acquired 467,035 shares as Gw Pharmaceuticals Plc (GWPH)’s stock declined 18.69%. The Scopia Capital Management Lp holds 3.46 million shares with $456.10M value, up from 2.99 million last quarter. Gw Pharmaceuticals Plc now has $4.25 billion valuation. The stock increased 2.05% or $3.03 during the last trading session, reaching $150.68. About 772,899 shares traded or 85.24% up from the average. GW Pharmaceuticals plc (NASDAQ:GWPH) has declined 9.18% since May 17, 2017 and is downtrending. It has underperformed by 20.73% the S&P500.

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Nasdaq.com which released: “GW Pharmaceuticals and US Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of …” on May 16, 2018, also Nasdaq.com with their article: “Why Marijuana Stock GW Pharmaceuticals Gained 18% in April” published on May 08, 2018, Investorplace.com published: “GW Pharmaceuticals Stock Slides on Q2 Earnings Miss” on May 08, 2018. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Seekingalpha.com and their article: “GW Pharmaceuticals’ (GWPH) CEO Justin Gover on Q2 2018 Results – Earnings Call Transcript” published on May 09, 2018 as well as Prnewswire.com‘s news article titled: “Cannabis is Fueling the Next Era of Medical Revolution” with publication date: May 16, 2018.

Scopia Capital Management Lp decreased Forest City Rlty Tr Inc stake by 1.28 million shares to 21.97M valued at $529.38 million in 2017Q4. It also reduced Spdr S&P 500 Etf Tr (Put) (SPY) stake by 3.64M shares and now owns 609,400 shares. Advanced Accelerator Applic was reduced too.

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 30 analyst reports since August 13, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Tuesday, August 8 with “Buy” rating. The stock has “Buy” rating by Evercore on Wednesday, August 16. On Thursday, December 28 the stock rating was maintained by Leerink Swann with “Buy”. The company was initiated on Thursday, August 13 by Morgan Stanley. The stock has “Outperform” rating by Leerink Swann on Tuesday, February 6. The company was maintained on Monday, September 26 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Tuesday, April 17 with “Buy”. As per Tuesday, February 6, the company rating was maintained by Bank of America. Maxim Group maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Monday, August 7 with “Buy” rating. As per Monday, December 4, the company rating was maintained by Cantor Fitzgerald.

Analysts await Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report earnings on August, 13. They expect $-0.54 EPS, up 27.03% or $0.20 from last year’s $-0.74 per share. After $-0.58 actual EPS reported by Gemphire Therapeutics Inc. for the previous quarter, Wall Street now forecasts -6.90% EPS growth.

Among 9 analysts covering Gemphire Therapeutics (GEMP), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics has $3100 highest and $15.0 lowest target. $25.11’s average target is 296.68% above currents $6.33 stock price. Gemphire Therapeutics had 18 analyst reports since August 30, 2016 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, September 12 with “Buy”. The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) earned “Buy” rating by H.C. Wainwright on Tuesday, November 14. Piper Jaffray initiated the shares of GEMP in report on Monday, April 10 with “Overweight” rating. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, May 31. The rating was initiated by Jefferies on Tuesday, August 30 with “Buy”. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, August 30. The rating was maintained by Jefferies on Wednesday, May 31 with “Buy”. On Friday, October 27 the stock rating was reinitiated by PiperJaffray with “Overweight”. The firm earned “Buy” rating on Tuesday, August 8 by Canaccord Genuity. As per Thursday, June 29, the company rating was maintained by Canaccord Genuity.

The stock increased 14.88% or $0.82 during the last trading session, reaching $6.33. About 1.41 million shares traded or 1173.27% up from the average. Gemphire Therapeutics Inc. (GEMP) has declined 45.18% since May 17, 2017 and is downtrending. It has underperformed by 56.73% the S&P500.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: